> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-59/
- Published: 2021-10-17T12:00:00.000Z
- Updated: 2026-09-14T17:19:17.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5150386

**Drug Distribution Security Public Meeting**  
10/14/2021 *Federal Register* notice: FDA has announced an 11/16 virtual public meeting entitled “Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act (DSCSA).” The meeting is intended to provide stakeholders an opportunity to discuss enhanced drug distribution security requirements of the DSCSA related to system attributes necessary to enable secure tracing of product at the package level. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-22474.pdf?ref=fdaweb.com).

**Some Class 1 Devices Exempt from UDI**  
10/13/2021 *Federal Register* notice: FDA has made available a draft guidance entitled S*elect Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices*. The document identifies certain Class 1 devices for which FDA does not intend to enforce Global Unique Device Identification Database submission requirements. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-22308.pdf?ref=fdaweb.com).

**Guide on Drug Continuous Manufacturing**  
10/13/2021 *Federal Register* notice: FDA has made available a draft guidance entitled *Q13 Continuous Manufacturing of Drug* Substances and Drug Products. The International Council for Harmonization document provides clarification on continuous manufacturing concepts and describes scientific approaches and regulatory considerations. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-22451.pdf?ref=fdaweb.com).

**Panel to Review Pfizer Covid Vaccine in Kids**  
10/12/2021 *Federal Register* notice: FDA has announced a 10/26 Vaccines and Related Biological Products Advisory Committee meeting. Panel members are scheduled to review and discuss Pfizer-BioNTech’s emergency use authorization amended request to administer their Covid-19 mRNA vaccine to children aged five through 11 years of age. To view the notice, click [here](https://public-inspection.federalregister.gov/2021-22452.pdf?ref=fdaweb.com).